Archive | Health Professionals

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma

The efficacy seen with ripretinib (Qinlock) in patients with KIT-mutated melanoma was higher than has been previously reported, according to Filip Janku, MD, PhD. Furthermore, the switch-control tyrosine kinase inhibitor (TKI) has elicited durable responses, even in patients who were heavily pretreated, making the drug a powerful tool for this patient population.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Larkin Unpacks the Effect of Anti–PD-L1 Therapy on TIL Activity in Melanoma

The role of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for patients with melanoma has undergone scrutiny as efforts to unpack the correlation between the duration of prior immunotherapy and efficacy outcomes.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Darovasertib/Crizotinib Shows Early Efficacy in Metastatic Uveal Melanoma

Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Boosting anti-cancer action by driving up immunity at tumor site

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest